Rob Mansfield

Rob Mansfield has extensive work experience in the pharmaceutical industry. Rob is currently an Executive Director at Metacrine, Inc. Prior to this, they served as a Sr. Director of Pharmaceutical Development at Triphase Accelerator Corporation from 2015 to 2017. In this role, they led and managed all CMC activities for drug substance and products, as well as evaluated and managed contract research organizations.

From 2007 to 2015, Mansfield held various roles at Tragara Pharmaceuticals, including Sr. Director of Pharmaceutical Development and Director of Formulation Development & Manufacturing. In these positions, they managed CMC activities, outsourcing, and project management. Rob also conducted competitive analysis and coordinated development efforts for biomarkers in clinical trials.

Before joining Tragara Pharmaceuticals, Mansfield worked at Conforma Therapeutics / Biogen Idec as a Director of Formulations & Analytical Development from 2002 to 2007. Rob provided formulation and analytical support for discovery and clinical trials, as well as managed the ambrubicin program.

From 1997 to 2002, Mansfield was the Director of Analytical & Preformulation at MDS Pharma Services (Xcelience). Rob established the analytical and preformulation group and assisted in formulation development programs.

Mansfield started their career as a Sr. Scientist at Bausch & Lomb Pharmaceuticals in 1996, where they focused on formulation development and analytical support. Rob then worked as a Scientist at Allergan in 1995, conducting analytical method development and support.

In the early 1990s, Mansfield worked at Gensia Pharmaceuticals / Automedics and Gensia, Inc., where they conducted formulation development and provided CMC support for animal studies and clinical trials.

Overall, Mansfield has a strong background in pharmaceutical development, CMC management, project management, and analytical support.

Rob Mansfield attended the University of Kentucky from 1987 to 1992, where they earned a Ph.D. in Pharmaceutical & Medicinal Chemistry. Following this, they pursued post-doctoral research at The University of Kansas from 1992 to 1993.